Nanobiotix Shares Decline After a 680% Surge Over a Year

Current Trading Session

This morning, Nanobiotix's share price is set at 27.30 euros, down from the previous day's close of 28.20 euros. Over the last seven days, the stock has lost 5.86%, showing signs of fatigue after a particularly strong quarter: the three-month performance still stands at 45.99%. Over twelve months, the valuation has nearly octupled, marking a remarkable journey for this company specializing in medical nanotechnologies. This decline occurs in a context of generalized weakness across European markets. The SBF 120 is down 1.65% during the session, while the DAX is stable. Among comparable healthcare sector stocks, Sanofi has slightly increased by 0.62%, whereas EssilorLuxottica has fallen by 1.60%. Nanobiotix's decline thus appears partly linked to the selling pressure affecting the entire Paris stock market, although its magnitude is more pronounced than that of the reference index.

Technical Analysis

From a graphical perspective, Nanobiotix's stock remains well above its 50-day and 200-day moving averages, located respectively at 21.98 euros and 14.50 euros. This significant gap — the stock is trading nearly 24% above the 50-day moving average — highlights the extent of the recent bullish movement but also signals a distancing that may encourage short-term profit-taking. The RSI, an indicator measuring the rate of price changes, is at 62. This level, still in the neutral zone but close to the overbought threshold of 70, indicates that buying pressure remains present without being excessive. The nearest technical resistance is positioned at 33.50 euros, about 23% above the current price, while the major support identified at 18.14 euros provides a distant fallback zone. The monthly volatility, measured at 28.06%, confirms that price fluctuations remain significant on this small-cap stock.